Asset Dedication LLC decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 21.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,016 shares of the company’s stock after selling 280 shares during the quarter. Asset Dedication LLC’s holdings in Sanofi were worth $49,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. Cascade Investment Advisors Inc. increased its stake in shares of Sanofi by 4.7% in the 1st quarter. Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock worth $1,670,000 after purchasing an additional 1,535 shares in the last quarter. Vestal Point Capital LP purchased a new stake in Sanofi in the fourth quarter worth about $14,919,000. Dynamic Advisor Solutions LLC increased its position in Sanofi by 39.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after buying an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC bought a new position in shares of Sanofi in the second quarter worth about $13,725,000. Finally, Oxbow Advisors LLC purchased a new position in shares of Sanofi during the 4th quarter valued at about $4,689,000. 10.04% of the stock is currently owned by institutional investors.
Sanofi Stock Performance
NASDAQ SNY opened at $58.51 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The business has a 50-day moving average price of $53.00 and a 200-day moving average price of $49.91. The firm has a market cap of $148.19 billion, a price-to-earnings ratio of 29.40, a price-to-earnings-growth ratio of 1.64 and a beta of 0.60.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 3rd. Argus increased their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $57.50.
Check Out Our Latest Stock Analysis on SNY
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
- Five stocks we like better than Sanofi
- How to Invest in Insurance Companies: A GuideĀ
- Why Block’s Key Components Make It a Solid Investment Choice
- How to Buy Cheap Stocks Step by Step
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Compound Interest and Why It Matters When Investing
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.